<DOC>
	<DOCNO>NCT02529930</DOCNO>
	<brief_summary>This exploratory , open , prospective multi-centre study VB10.16 immunotherapy patient high grade HPV16+ Cervical Intraepithelial Neoplasia ( HSIL ; CIN2/3 ) . This study recruit approximately 27-40 female patient high grade cervical intraepithelial neoplasia ( HSIL , CIN 2/3 ) multiple sit Europe .</brief_summary>
	<brief_title>An Exploratory Safety Immunogenicity Study HPV16+ Immunotherapy VB10.16 Women With HSIL ; CIN 2/3 )</brief_title>
	<detailed_description>The study divide two phase , dose expansion phase . During dose phase safety , tolerability immunogenicity 2 different vaccination schedule 3 mg VB10.16 immunotherapy establish minimum 12 patient histology confirm CIN 2 . During expansion phase safety , tolerability immunogenicity select vaccination schedule evaluate approximately 15 20 patient histology confirm HPV16+ CIN 2/3 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : 1 . Women â‰¥18 year 2 . Women ectocervical HPV16+ associate High Grade Cervical Intraepithelial Neoplasia ( HSIL ) verify local pathology : ( Dosing Phase : Women histologically confirm HPV16+ associate CIN 2 ; Expansion Phase : Women histologically confirm HPV16+ associate CIN 2/3 ) 3 . Satisfactory colposcopic examination . Exclusion Criteria ( abbreviate ) : 1 . More 2 cervical quadrant CIN 3 visualise colposcopy . 2 . Atypical glandular cell ( AGC ) adenocarcinoma situ ( AIS ) cytology , malignant cell cytology histology suspicion either microinvasive invasive disease . 3 . Current severe pelvic inflammatory disease , severe cervicitis , severe gynaecological infection per colposcopy clinical examination . 4 . Positive serological test hepatitis C virus hepatitis B virus surface antigen ( HBsAg ) human immunodeficiency virus ( HIV ) . 5 . Administration blood product within 3 month enrolment . 6 . Concomitant prior malignant disease . 7 . Clinically significant autoimmune disease . 8 . Known allergy Kanamycin aminoglycosides 9 . Known immunodeficiency immunosuppression . 10 . History toxic shock syndrome . 11 . Evidence history clinically significant cardiac disease 12 . Active infection require parenteral antibiotic . 13 . Tattoos , scar , active lesions/rashes within 2 cm site vaccination implantable lead . 14 . Immunosuppression 15 . Major surgery within 3 month trial entry . 16 . Current recent ( within 30 day first study treatment ) participation clinical trial . 17 . Previous vaccination ( either therapeutic and/or prophylactic ) HPV . 18 . Administration live vaccine within 90 day trial entry . 19 . Concomitant anticancer therapy . 20 . Inadequate bone marrow function 21 . Inadequate liver function 22 . Clinical significant electrolyte abnormality 23 . Women childbearing age willing use effective form contraception 24 . Pregnancy intention become pregnant 25 . Nursing woman 26 . Evidence medical condition may interfere study participation , patient compliance place patient high risk treatmentrelated complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HSIL</keyword>
	<keyword>CIN 2/3</keyword>
	<keyword>Therapeutic DNA vaccine</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>